Search This Blog

Sunday, June 23, 2013

New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA (NYSE:LLY)

New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.